Literature DB >> 25188759

Effects of antihypertensive treatment on cardiovascular autonomic control: a prospective study.

Anton R Kiselev1, Vladimir I Gridnev, Mikhail D Prokhorov, Anatoly S Karavaev, Olga M Posnenkova, Vladimir I Ponomarenko, Boris P Bezruchko.   

Abstract

OBJECTIVE: The aim of study was to propose an approach to the control of dynamics of autonomic dysfunction in cardiovascular system (CVS) under antihypertensive treatment (AT) in patients with arterial hypertension (AH), based on individual features of synchronization of 0.1-Hz rhythms in heart rate (HR) and photoplethysmogram (PPG) and spectral indices of heart rate variability (HRV).
METHODS: We designed prospective cohort diagnostic accuracy and studied 105 AH patients (66 females) aged 47±8 years during 8 weeks. The HRV spectral indices and the index S of synchronization between the 0.1-Hz rhythms in HR and PPG during a tilt test are compared in their ability to control the AT with angiotensin-converting enzyme inhibitors (ACE-Is) (fosinopril or enalapril) and β-blockers (atenolol or metoprolol). We apply Shapiro-Wilk, Mann-Whitney U and Wilcoxon tests.
RESULTS: It is shown that the power of low-frequency (LF) band in HRV spectrum and index S can be used as criteria for initial assessment of the status of autonomic regulation in AH patients. The patients with S<25% in vertical body's position and LF>250 ms2 in horizontal body's position require ACE-Is treatment. The AH patients with LF<350 ms2 and S<30% in vertical body's position require β-blocker treatment. The AH patients with S>25% and LF>250 ms2 in horizontal body's position do not require any ACE-Is or β-blocker treatment. Both drug groups can be used in patients with low values of index S and low power of LF band in HRV spectrum.
CONCLUSION: The control of AT can be carried out in AH patients taking into account the individual features of autonomic dysfunction in CVS. Sensitivity and specificity of our approach were 65% and 73%, respectively.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25188759     DOI: 10.5152/akd.2014.5107

Source DB:  PubMed          Journal:  Anadolu Kardiyol Derg        ISSN: 1302-8723


  6 in total

1.  Heart rate variability in restless legs syndrome and periodic limb movements of Sleep.

Authors:  Daniel A Barone; Matthew R Ebben; Miles DeGrazia; David Mortara; Ana C Krieger
Journal:  Sleep Sci       Date:  2017 Apr-Jun

2.  Associations between Heart Rate Variability Parameters and Hemodynamic Profiles in Patients with Primary Arterial Hypertension, Including Antihypertensive Treatment Effects.

Authors:  Małgorzata Maciorowska; Paweł Krzesiński; Robert Wierzbowski; Beata Uziębło-Życzkowska; Grzegorz Gielerak
Journal:  J Clin Med       Date:  2022-06-29       Impact factor: 4.964

3.  Correlations Between Cardiovascular Autonomic Control Indices During the Two-hour Immobilization Test in Healthy Subjects.

Authors:  A R Kiselev; V A Shvartz; A S Karavaev; S A Mironov; V I Ponomarenko; V I Gridnev; M D Prokhorov
Journal:  Open Cardiovasc Med J       Date:  2016-03-07

4.  Novel results and future perspectives of study of cardiovascular autonomic control in prediabetic patients.

Authors:  Anton R Kiselev; Vladimir A Shvartz; Olga L Bockeria
Journal:  Anatol J Cardiol       Date:  2016-10       Impact factor: 1.596

5.  Comparative study of short-term cardiovascular autonomic control in cardiac surgery patients who underwent coronary artery bypass grafting or correction of valvular heart disease.

Authors:  Vladimir A Shvartz; Anton R Kiselev; Anatoly S Karavaev; Kristina A Vulf; Ekaterina I Borovkova; Mikhail D Prokhorov; Andrey D Petrosyan; Olga L Bockeria
Journal:  J Cardiovasc Thorac Res       Date:  2018-03-17

6.  Mathematical modeling of the cardiovascular autonomic control in healthy subjects during a passive head-up tilt test.

Authors:  Yurii M Ishbulatov; Anatoly S Karavaev; Anton R Kiselev; Margarita A Simonyan; Mikhail D Prokhorov; Vladimir I Ponomarenko; Sergey A Mironov; Vladimir I Gridnev; Boris P Bezruchko; Vladimir A Shvartz
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.